HOME > About SEKISUI > What's New Archive > 2016 > Merger of 2 Medical Companies in the Sekisui Chemical Group

About SEKISUI
What's New Archive

Press Release
Merger of 2 Medical Companies in the Sekisui Chemical Group
Apr 20, 2016

SEKISUI CHEMICAL CO., LTD
SEKISUI MEDICAL CO., LTD.
EIDIA Co., Ltd.

SEKISUI CHEMICAL CO., LTD. (President and Representative Director: Teiji Koge, hereinafter called "Sekisui Chemical") has decided to merge the two subsidiaries of SEKISUI MEDICAL CO., LTD. (Representative Director and CEO: Hideo Tagashira, hereinafter called "Sekisui Medical") and EIDIA Co., Ltd. (Representative Director and CEO: Takeshi Yokoo, hereinafter called "EIDIA") as of April 1st, 2017, which are administrated by Sekisui Chemical's High Performance Plastics Company, with SEKISUI MEDICAL CO., LTD. as the surviving company.

The purpose of this merger, interested companies, and the post-merger company, are described below.



--Agenda--

1. Background and Purpose of the Merger

Sekisui Medical and EIDIA are operating medical businesses, in which their cores are diagnostic business.
Sekisui Chemical examined its policy for the early indications and maximization of the synergy between both Sekisui Medical and EIDIA after the acquisition of all EIDIA shares, and concluded that it was necessary to merge both companies.

Following the merger, the aim is to achieve the 5-year midterm business plan "HIYAKU 2020"* starting from FY2016 to FY2020 in our medical businesses, by strengthening all operations, configuring the efficient organizational system in the functions of Sales & Marketing, Production, R&D, and Head Office, while simultaneously promoting the creation of the innovation through the fusion of the business cultures and personnel of both companies. 


*1: Announced on January 14, 2016. See the following website.SEKISUI MEDICAL Midterm Management Strategy


2. Summary of Interested Companies 

(as of April 20, 2016)


Surviving Company

Absorbed Company

 (1) Company Name

  SEKISUI MEDICAL CO., LTD.

  EIDIA Co., Ltd.

 (2) Head Office Address

  Chuo-ku, Tokyo

  Chiyoda-ku, Tokyo

 (3) Business Details

  Diagnostics, Drug Development Solutions,   Pharmaceuticals and Fine Chemicals

Diagnostic sales, Clinical Analyzers, Laboratory Reagents, and Physics and Chemical equipment

 (4) Spokesperson

  President and CEO Hideo Tagashira

  President and CEO Takeshi Yokoo

 (5) Capital

  1,275 million JPY

  5,262.48 million JPY

 (6) Established

  July 1947

  May 1954

 (7) Shareholders and
    Share Holdings Ratio

  SEKISUI CHEMICAL CO., LTD. 100% 

  SEKISUI CHEMICAL CO., LTD. 100%

 (8) Sales

  36,711 million JPY (To March 2015)

  6,285 million JPY (To March 2015)


3. Post-Merger Company

1) Company Name


The Surviving company will continue the name of SEKISUI MEDICAL CO., LTD..

2) Date of Merger


April 1, 2017

3) Base of Operations (at the time of consolidation)


-Prior to merging, the head office operations of both companies will be consolidated and transferred close to the current Head Office of Sekisui Medical .

-The current Production and R&D bases will be maintained for both companies, however the reorganization and the optimization of operations for the nearby Production and R&D bases in Ibaraki Prefecture is still under examination.


Business Bases at the time of Consolidation (Objective)

  Head Office

Head Office operations of both companies will be consolidated and transferred.

  Production Bases: 4

Tsukuba plant (Ryugasaki, Ibaraki Prefecture), Iwate plant (Hachimantai, Iwate Prefecture), Amagasaki plant (Amagasaki, Hyogo Prefecture), and Ibaraki Production Dept. Office*2 (Inashiki District, Ibaraki Prefecture)

  Research and Development
  Bases: 5

Tsukuba R&D Laboratory, (Ryugasaki, Ibaraki Prefecture), Iwate R&D Center (Hachimantai, Iwate Prefecture), Tokai R&D Center (Tokai, Ibaraki Prefecture), Amagasaki R&D Center (Amagasaki, Hyogo Prefecture), and Ibaraki Office R&D Unification Dept.*2 (Inashiki District, Ibaraki Prefecture)

  Sales Offices: 10

EIDIA's sales operations will be consolidated into the 10 existing Sekisui Medical offices


*2: Current EIDIA bases. The others are Sekisui Medical bases.


4. Impact on Business Results

The impact of this consolidation expected in Sekisui Chemical’s consolidated financial statement for this period (FY2016) is minimal. Further, Sekisui Chemical's Consolidated Financial Settlement Forecasts for this period are scheduled to be announced on April 27, 2016.

--Ends--


Press Contact

SEKISUI CHEMICAL CO., LTD.
Public Relations Group, Business Strategy Department
Fax: +81-(0)3-5521-0510


Disclaimer

This press release may contain forward-looking statements. Such forward-looking statements are based on current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements due to changes in global economic, business, competitive market and regulatory factors.
Page Top